148 related articles for article (PubMed ID: 35819745)
41. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
Blair AB; Groot VP; Gemenetzis G; Wei J; Cameron JL; Weiss MJ; Goggins M; Wolfgang CL; Yu J; He J
J Am Coll Surg; 2018 Apr; 226(4):630-637.e1. PubMed ID: 29309945
[TBL] [Abstract][Full Text] [Related]
42. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
43. Mixed neuroendocrine non-neuroendocrine neoplasm: a case report and review.
Hiroi S; Yamamoto R; Hamaoka M; Hoshino M; Sasaki T; Matsugu Y; Nishisaka T; Nakahara H; Itamoto T
Clin J Gastroenterol; 2022 Feb; 15(1):244-255. PubMed ID: 34796444
[TBL] [Abstract][Full Text] [Related]
44. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.
Fountzilas E; Konstantopoulou I; Vagena A; Apostolou P; Papadimitriou C; Christodoulou C; Tryfonopoulos D; Manousou K; Delimitsou A; Papamentzelopoulou M; Fountzilas G; Yannoukakos D; Fostira F
Clin Breast Cancer; 2020 Apr; 20(2):152-159. PubMed ID: 31980407
[TBL] [Abstract][Full Text] [Related]
45. Low incidence of BRCA2 mutations in breast carcinoma and other cancers.
Teng DH; Bogden R; Mitchell J; Baumgard M; Bell R; Berry S; Davis T; Ha PC; Kehrer R; Jammulapati S; Chen Q; Offit K; Skolnick MH; Tavtigian SV; Jhanwar S; Swedlund B; Wong AK; Kamb A
Nat Genet; 1996 Jun; 13(2):241-4. PubMed ID: 8640236
[TBL] [Abstract][Full Text] [Related]
46. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic.
Winter C; Nilsson MP; Olsson E; George AM; Chen Y; Kvist A; Törngren T; Vallon-Christersson J; Hegardt C; Häkkinen J; Jönsson G; Grabau D; Malmberg M; Kristoffersson U; Rehn M; Gruvberger-Saal SK; Larsson C; Borg Å; Loman N; Saal LH
Ann Oncol; 2016 Aug; 27(8):1532-8. PubMed ID: 27194814
[TBL] [Abstract][Full Text] [Related]
47. Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient.
Randall TC; Bell KA; Rebane BA; Rubin SC; Boyd J
Gynecol Oncol; 1998 Sep; 70(3):432-4. PubMed ID: 9790802
[TBL] [Abstract][Full Text] [Related]
48. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR
PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669
[TBL] [Abstract][Full Text] [Related]
49. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil.
Carraro DM; Koike Folgueira MA; Garcia Lisboa BC; Ribeiro Olivieri EH; Vitorino Krepischi AC; de Carvalho AF; de Carvalho Mota LD; Puga RD; do Socorro Maciel M; Michelli RA; de Lyra EC; Grosso SH; Soares FA; Achatz MI; Brentani H; Moreira-Filho CA; Brentani MM
PLoS One; 2013; 8(3):e57581. PubMed ID: 23469205
[TBL] [Abstract][Full Text] [Related]
50. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
51. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.
Fogelman DR; Wolff RA; Kopetz S; Javle M; Bradley C; Mok I; Cabanillas F; Abbruzzese JL
Anticancer Res; 2011 Apr; 31(4):1417-20. PubMed ID: 21508395
[TBL] [Abstract][Full Text] [Related]
52. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
53. PALB2 analysis in BRCA2-like families.
Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
[TBL] [Abstract][Full Text] [Related]
54. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions.
Lucas AL; Shakya R; Lipsyc MD; Mitchel EB; Kumar S; Hwang C; Deng L; Devoe C; Chabot JA; Szabolcs M; Ludwig T; Chung WK; Frucht H
Clin Cancer Res; 2013 Jul; 19(13):3396-403. PubMed ID: 23658460
[TBL] [Abstract][Full Text] [Related]
55. Collision of a pancreatic ductal adenocarcinoma and a pancreatic neuroendocrine tumor associated with multiple endocrine neoplasm type 1.
Ohno A; Fujimori N; Miki M; Oono T; Igarashi H; Matsuda R; Koga Y; Oda Y; Ohtsuka T; Nakamura M; Ito T; Ogawa Y
Clin J Gastroenterol; 2021 Feb; 14(1):358-363. PubMed ID: 32951175
[TBL] [Abstract][Full Text] [Related]
56. Genetic alterations in gastric amphicrine carcinomas and comparison with gastric mixed neuroendocrine-non-neuroendocrine neoplasms.
Sun L; Wang C; Zhang J; Shao B; Zhao S; Guo Y; Li X; Sun Y
Mod Pathol; 2022 Jun; 35(6):808-815. PubMed ID: 34839352
[TBL] [Abstract][Full Text] [Related]
57. Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer.
Skoulidis F; Cassidy LD; Pisupati V; Jonasson JG; Bjarnason H; Eyfjord JE; Karreth FA; Lim M; Barber LM; Clatworthy SA; Davies SE; Olive KP; Tuveson DA; Venkitaraman AR
Cancer Cell; 2010 Nov; 18(5):499-509. PubMed ID: 21056012
[TBL] [Abstract][Full Text] [Related]
58. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers.
Iqbal J; Ragone A; Lubinski J; Lynch HT; Moller P; Ghadirian P; Foulkes WD; Armel S; Eisen A; Neuhausen SL; Senter L; Singer CF; Ainsworth P; Kim-Sing C; Tung N; Friedman E; Llacuachaqui M; Ping S; Narod SA;
Br J Cancer; 2012 Dec; 107(12):2005-9. PubMed ID: 23099806
[TBL] [Abstract][Full Text] [Related]
59. Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients.
Noh JM; Choi DH; Nam SJ; Lee JE; Kim JW; Kim SW; Kang E; Lee MH; Ahn SH; Kim KS; Park SK; Haffty BG;
Breast Cancer Res Treat; 2012 Jan; 131(1):217-22. PubMed ID: 21847643
[TBL] [Abstract][Full Text] [Related]
60. Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer.
Zhou C; Porter N; Borges M; Gauthier C; Ferguson L; Huang B; Nanda N; He J; Laheru D; Hruban RH; Goggins M; Klein AP; Roberts NJ
Pancreatology; 2021 Aug; 21(5):938-941. PubMed ID: 33839031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
